Info

🌱 來自：Hormone-receptor positive (HER2 negative)-of-metastatic breast cancer

CDK4_6i

tldr-of-CDK4_6i

• Differential Toxicities of CDK4/6 Inhibitor Therapy
  • Palbociclb
    • 125mg qD
    • (3 wks on, 1 wk off)
    • No CNS penetration
    • 95% of patients experience common adverse events (AE)
    • Neutropenia in 54% of patients with Grade 3/4 severity
    • Diarrhea in 16% of patients
    • Crincrease in NR% of patients
    • QTc increase in NR% of patients
  • Abemaciclb
    • 200mg BID (continuously)
    • CNS penetration
    • 88% of patients experience common AE
    • Neutropenia in 0% of patients with Grade 3/4 severity
    • Diarrhea in 90% of patients
    • Crincrease in 98.5% of patients
    • QTc increase in NR% of patients
  • Ribociclib
    • 600mg qD (3 wks on, 1 wk off)
    • No CNS penetration
    • 46% of patients experience common AE
    • Neutropenia in 29% of patients with Grade 3/4 severity
    • Diarrhea in 22% of patients
    • Crincrease in NR% of patients
    • QTc increase in 8% of patients with Grade 3/4 severity

References

Considering Adjuvant CDK4/6 Inhibitors?: monarchE and NATALEE in Clinical Practice